Semaglutide Significantly Reduces Long-Term Diabetes Risk Among Obesity Patients - MD Magazine

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

Once-weekly 2.4 mg semaglutide is associated with an approximate 60% reduced risk of type 2 diabetes in patients with obesity, according to new findings presented at the American Diabetes Association… [+3708 chars]

full article...